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Anemia is one of the easiest diagnoses in clinical prac-tice, being based on a widely available and cheap lab-oratory parameter: hemoglobin concentration. In the
near future, this diagnosis could become even simpler
through a smartphone app.1 Nonetheless, anemia is fre-
quently overlooked, particularly when it is mild (e.g. hemo-
globin values >10 g/dL but <12 g/dL or <13 g/dL in females
and males, respectively) and no obvious symptoms are
apparently associated. This typically occurs in the elderly, in
whom other co-morbidities are often present, distracting the
attention of physicians and caregivers.2 Indeed, the preva-
lence of anemia in people aged >65 years is high, ranging
from nearly 12% in those living in the community to more
than 45% in institutionalized nursing-home residents.2
While a mild anemia has been traditionally considered as a
“physiological” consequence of aging, more recent studies
have shown that the decline in hemoglobin is minimal, if
any, in the “wellderly”, namely people aging well without
significant comorbidities.3 Moreover, growing evidence sug-
gests that anemia in the elderly is not an innocent bystander,
being strongly and independently associated with a number
of adverse outcomes, including cognitive decline, reduced
physical performance, increased risk of falls and fractures,
and even increased mortality.2 In this issue of Haematologica,
Wouters and colleagues report the results of the large
Lifelines Cohort Study, confirming that anemia in the elderly
is negatively associated with either quality of life or
survival.4 A key point of anemia in the elderly lies in the dif-
ficulty of establishing the etiology, which in turn should
drive its management. While anemia in young people is gen-
erally due to a single cause (e.g. iron deficiency in pre-
menopausal women with heavy menstrual bleeding), ane-
mia in the elderly is often multifactorial, reflecting the typi-
cal multimorbidity of aged people.5 This frequently makes it
hard to dissect out the main mechanism leading to anemia in
a given elderly individual. For example, iron deficiency in the
elderly can be due to a mixture of malnutrition, malabsorp-
tion and bleeding, often aggravated by multiple medication
use.6 Such difficulty is even more pronounced in large epi-
demiological surveys, such as the Lifelines Study, in which
only three general subcategories of anemia can be distin-
guished, based on a few available laboratory parameters:
nutritional deficiencies, anemia of inflammation (also named
anemia of chronic diseases), and “unexplained” anemia,7
each of them accounting roughly for one third of cases.
Notwithstanding these inherent limitations, the study by
Wouters and colleagues points out anemia of inflammation
as the most detrimental subcategory in the elderly, because
of the strongest association with quality of life and mortali-
ty. This is somewhat at variance with the findings of other
studies, in which subjects with anemia due to nutritional
deficiency showed the worst prognosis.8 Such a discrepancy
reflects the uncertainty in the correct etiological classifica-
tion of anemia in the elderly, as well as our limited knowl-
edge in the field. The broad category of “unexplained ane-
mia” well illustrates this gap, although it likely represents a
heterogeneous group of conditions that cannot be adequate-
ly addressed by large epidemiological surveys because of
the need for second level laboratory tests. Such conditions
include androgen deficiency, vitamin D deficiency, unrecog-
nized iron deficiency with apparently normal traditional
biomarkers, impaired bone marrow response to erythropoi-
etin, clonal hematopoiesis, and “inflammaging”.2 Of note,
recent advances suggest that the last two conditions may
share a relevant role in the pathophysiology of anemia in
the elderly, both by inducing a low-grade chronic inflamma-
tory status (Figure 1). Clonal hematopoiesis refers to age-
related acquisition of somatic mutations in certain driver
genes (e.g. TET2, DNMT3A, and JAK2) in hematopoietic
stem cells, conferring them a competitive advantage and
hence giving rise to a clonal progeny in the peripheral blood,
at variance with normal polyclonal hematopoiesis.9 Clonal
hematopoiesis is detectable through next-generation
sequencing studies in nearly 10% of 70-year old individuals
without abnormalities of peripheral blood cell counts and,
in these people, is a risk factor for subsequent development
of myeloid neoplasms. This is generally associated with
accumulation of multiple mutations, but the rate of progres-
sion appears as low as 0.5% per year. Such a condition has
been termed clonal hematopoiesis of indeterminate poten-
tial (CHIP), since, in fact, most carriers of clonal
hematopoiesis will never develop myeloid neoplasms.
Nevertheless, individuals with CHIP have been found at
increased risk of mortality due to cardiovascular events,
rather than to hematologic complications.10 Mounting evi-
dence suggests that accelerated atherosclerosis in CHIP is
associated with a systemic pro-inflammatory status driven
by abnormal clonal leukocytes deriving from mutated
hematopoietic stem cells.11 On the other hand, “inflammag-
ing” also contributes to a chronic upregulation of pro-
inflammatory cytokines in the elderly. This phenomenon is
thought to be the result of activation of the nuclear factor-
κB/inflammasome pathway driven by the so-called dam-
aged-associated molecular pattern, i.e., endogenous altered
molecules and reactive oxygen species that accumulate with
aging.12,13 Reciprocal influences between CHIP and “inflam-
maging” are likely, for example considering that reactive
oxygen species can also cause genomic instability, and that
subclinical inflammation by itself can prime a detrimental
vicious circle in tumorigenesis.14 The exact proportions by
which CHIP and “inflammaging” actually contribute to
unexplained anemia in the elderly deserve further studies.
Similarly, whether or not chronic subclinical inflammation,
which is difficult to detect using classical biomarkers such
as C-reactive protein, contributes to anemia through the
same mechanisms as those associated with overt inflamma-
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tion (e.g. hepcidin-driven iron-restricted erythropoiesis
and cytokine-mediated suppression of erythropoiesis)
remains to be demonstrated. Of note, clonal
hematopoiesis can also cause anemia because of ineffec-
tive erythropoiesis, since progenitors carrying certain
mutations can have a proliferative advantage over nor-
mal hematopoietic stem cells, but are less able to differ-
entiate adequately.15 Indeed, clonal hematopoiesis has
been identified in a high proportion (64%) of elderly
with unexplained cytopenia, for example with anemia
not fulfilling all the morphological and cytogenetic crite-
ria for the diagnosis of myelodysplastic syndrome.16 In
such cases, the term “clonal cytopenia of undetermined
significance” has been proposed.9
Finally, a key point to be kept in mind when thinking
about anemia in the elderly is that its robust association
with mortality, even independently of the many possible
confounders, does not prove a causal link, because of
inherent limitations of observational epidemiology.2 The
only way to prove causality definitively would be the
reduction of mortality and/or other adverse outcomes
after successful correction or amelioration of anemia. The
increasing number of promising anti-anemic drugs that
are entering the clinical arena, including hepcidin antago-
nists,17 novel iron formulations,18 activin receptor IIA lig-
and trap,19 and hypoxia inducible factor stabilizers,20 may
represent an unprecedented opportunity to clarify this
crucial point in the near future. 
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Figure 1. The complex relationship among aging, inflammation, and anemia. Clonal hematopoiesis and “inflammaging” are increasingly recognized as age-related
conditions (see the text). Both are able to induce a mild chronic pro-inflammatory status, and can influence each other in a vicious circle. For example, chronic inflam-
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the classical anemia of overt inflammation. It is worth noting that clonal hematopoiesis is also able to induce anemia because of ineffective erythropoiesis. When
cytopenia occurs in association with clonal hematopoiesis, it is termed clonal cytopenia of undetermined significance. Anemia in the elderly is strongly and independ-
ently associated with adverse outcomes, but whether or not this relationship is actually causal remains to be demonstrated. CV: cardiovascular; CCUS: clonal cytope-
nia of undetermined significance.     
Editorials
haematologica | 2019; 104(3) 419
Targeting a major hub of cell fate decisions – the mitochondrial-associated membrane
William L. Carroll and Nikki A. Evensen
Departments of Pediatrics and Pathology, Perlmutter Cancer Center, NYU-Langone Medical Center, New York, NY, USA
E-mail: WILLIAM L. CARROLL - william.carroll@nyumc.org
doi:10.3324/haematol.2018.208355
2. Girelli D, Marchi G, Camaschella C. Anemia in the elderly.
HemaSphere. 2018;2(3):e40.
3. Erikson GA, Bodian DL, Rueda M, et al. Whole-genome sequencing
of a healthy aging cohort. Cell. 2016;165(4):1002-1011.
4. Wouters H, van der Klauw MM, de Witte T, et al. Association of ane-
mia with health-related quality of life and survival: a large popula-
tion-based cohort study. Haematologica. 2019;104(3):468-476.
5. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B.
Epidemiology of multimorbidity and implications for health care,
research, and medical education: a cross-sectional study. Lancet.
2012;380(9836):37-43.
6. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the
elderly population, revisited in the hepcidin era. Front Pharmacol.
2014;5:83.
7. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood.
2018 Nov 6 [Epub ahead of print].
8. Shavelle RM, MacKenzie R, Paculdo DR. Anemia and mortality in
older persons: does the type of anemia affect survival? Int J Hematol.
2012;95(3):248-256.
9. Steensma DP. Clinical consequences of clonal hematopoiesis of inde-
terminate potential. Blood Adv. 2018;2(22):3404-3410.
10. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk
of atherosclerotic cardiovascular disease. N Engl J Med.
2017;377(2):111-121.
11. Libby P, Ebert BL. CHIP (clonal hematopoiesis of indeterminate
potential). Circulation. 2018;138(7):666-668.
12. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolu-
tionary perspective on immunosenescence. Ann N Y Acad Sci.
2000;908:244-254.
13. Youm YH, Grant RW, McCabe LR, et al. Canonical Nlrp3 inflamma-
some links systemic low-grade inflammation to functional decline in
aging. Cell Metab. 2013;18(4):519-532.
14. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and
cancer. Cell. 2010;140(6):883-899.
15. Qu X, Zhang S, Wang S, et al. TET2 deficiency leads to stem cell fac-
tor-dependent clonal expansion of dysfunctional erythroid progeni-
tors. Blood. 2018;132(22):2406-2417.
16. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of
somatic mutation in unexplained blood cytopenia. Blood.
2017;129(25):3371-3378.
17. Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in
drug discovery and delivery. Nat Rev Drug Discov. 2017;16(6):400-
423.
18. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron
replacement therapy: clinical and pathophysiological insights. Int J
Hematol. 2018;107(1):16-30.
19. Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the
treatment of anaemia in patients with lower-risk myelodysplastic
syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-
finding study with long-term extension study. Lancet Oncol.
2017;18(10):1338-1347.
20. Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase
inhibitors: a potential new treatment for anemia in patients with
CKD. Am J Kidney Dis. 2017;69(6):815-826.
Great progress has been made in the treatment ofhuman cancer but, unfortunately, there remainsan abundance of treatment failures due to pri-
mary therapy resistance and/or the emergence of drug
refractory clones. This is certainly true for acute
leukemias, which are the most common malignancies in
children and while they make up a smaller fraction of
cancer in adults, their impact is substantial given the
poorer outcome.  Furthermore, the high doses of cytotox-
ic agents that are often used in therapy are associated
with short- and long-term side effects. Thus, there is an
urgent need to develop novel therapeutic approaches to
improve outcome and decrease side effects. One such
strategy, taken by Koczian and colleagues and described
in this issue of Haematologica, is to augment the effective-
ness of conventional agents.1 They report that the use of
the small molecule inhibitor of protein disulfide iso-
merase (PDI), PS89, has a significant impact on the effec-
tiveness of cytostatic agents used routinely in the therapy
of acute leukemias. The model that emerges is that PS89
amplifies the apoptotic stimulus induced by cytotoxic
therapy, thereby allowing for increased efficacy at lower
doses, through modulation of proteins at the mitochondr-
ial-endoplasmic reticulum (ER) interface. The agent itself
has poor pharmacokinetic properties limiting in vivo
examination, but the results indicate substantial benefit
and a wide therapeutic index. Much work remains to be
done but the results emphasize the opportunity to target
a unique intracellular sub-compartment that plays a key
role in cell fate decisions: the interface between the ER
and mitochondria.
Mitochondria are multifaceted organelles responsible
for an array of cell functions critical for energy produc-
tion, redox balance, adaptation to cell stress, and activa-
tion of the intrinsic apoptotic pathway. They make up
20% of the cytoplasmic volume of a cell and are dynamic,
motile structures constantly altering shape through fis-
sion and fusion. These alterations involve two lipid bilay-
ers that make up the inner membrane forming cristae
(containing membrane-bound enzymes involved in
oxidative phosphorylation) which enclose the matrix,
and the smooth outer membrane. Mitochondria make
important contact with other organelles, particularly the
ER, which is in direct contacts with 20% of the mito-
chondrial surface. Changes in energy metabolism related
to cancer, the so-called Warburg effect, have received
renewed interest, especially with the discovery of “onco-
metabolites”, but changes that occur at the mitochondri-
al-ER interface are also critical in controlling mitochondr-
ial metabolism and cell fate decisions.2
The mitochondrial-ER interface, commonly referred to
as the mitochondria-associated membrane (MAM), is a
proteinaceous tether facilitating bidirectional communi-
cation between the two organelles controlling the balance
between survival and death.3,4 The exchange of metabo-
lites and contact at the interface controls energy produc-
